Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament

Journal of Neuroimmunology

Volumn 252, Issue 1-2, 2012, Pages 100-105

  Bartos, Ales ^a,b   Fialová, Lenka ^c   Sřvarcová, Jana ^c   Ripova, Daniela ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer disease; Antibody; Cerebrospinal fluid; Neurofilament; Serum; Tau protein

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; NEUROFILAMENT HEAVY SUBUNIT PROTEIN ANTIBODY; NEUROFILAMENT LIGHT SUBUNIT PROTEIN ANTIBODY; PROTEIN ANTIBODY; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; ALZHEIMER DISEASE; AUTOANTIBODIES; AUTOANTIGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEUROFILAMENT PROTEINS; TAU PROTEINS;

EID: 84867142068     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.08.001     Document Type: Article

References (57)

1. Bartos A., Stourac P., Rusina R., Sejdová M., Velenská Z. Paraneoplastic cerebellar degeneration associated with ovarian cancer: anti-Yo immunoreactivity in autoptic cerebellum and ovarian carcinoma. Nervenarzt 2002, 73:995-998.
2. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 2007, 254:20-25.
3. Bartos A., Fialová L., Soukupová J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 2007, 116:100-107.
4. Bartoš A., Zach P., Diblíková F., Tinteřra J., Ř́pová D., Brunovský M. Visual rating of medial temporal lobe atrophy on magnetic resonance imaging in Alzheimer's disease. Psychiatrie 2007, 11:49-52.
5. Bartosř A., Raisová M., Kopecřek M. Amendment of the Czech Addenbrooke's cognitive examination (ACE-CZ). Cesk. Slov. Neurol. N. 2011, 74:681-684.
6. Bartosř A., Raisová M., Kopecřek M. The reasons and the process of amendment of the Czech Addenbrooke's cognitive examination (ACE-CZ). Cesk. Slov. Neurol. N. 2011, 74:e1-e5.
7. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 2010, 224:472-485.
8. Bouras C., Riederer B.M., Kövari E., Hof P.R., Giannakopoulos P. Humoral immunity in brain aging and Alzheimer's disease. Brain Res. Brain Res. Rev. 2005, 48:477-487.
9. Brandt R. Cytoskeletal mechanisms of neuronal degeneration. Cell Tissue Res. 2001, 305:255-265.
10. Cairns N.J., Lee V.M.-Y., Trojanowski J.Q. The cytoskeleton in neurodegenerative diseases. J. Pathol. 2004, 204:438-449.
11. Colasanti T., Barbati C., Rosano G., Malorni W., Ortona E. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun. Rev. 2010, 9:807-811.
12. D'Andrea M.R. Add Alzheimer's disease to the list of autoimmune diseases. Med. Hypotheses 2005, 64:458-463.
13. Deisenhammer F., Bartos A., Egg R., Gilhus N.E., Giovannoni G., Rauer S., Sellebjerg F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur. J. Neurol. 2006, 13:913-922.
14. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
15. Dujmovic I. Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult. Scler. Int. 2011, 2011:767083.
16. Fialova L., Bartos A., Svarcova J., Malbohan I. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 2011, 6:e27476.
17. Fialova L., Svarcova J., Bartos A., Malbohan I. Avidity of antineurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol. 2012, 57:415-419.
18. Franceschi M., Comola M., Nemni R., Pinto P., Iannaccone S., Smirne S., Canal N. Neuron-binding antibodies in Alzheimer's disease and Down's syndrome. J. Gerontol. 1989, 44:M128-M130.
19. Goñi F., Sigurdsson E.M. New directions towards safer and effective vaccines for Alzheimer's disease. Curr. Opin. Mol. Ther. 2005, 7:17-23.
20. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J. Neurol. 2010, 257:509-517.
21. Gu J., Sigurdsson E.M. Immunotherapy for tauopathies. J. Mol. Neurosci. 2011, 45:690-695.
22. Hort J., Bartos A., Pirttilä T., Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur. J. Neurol. 2010, 17:90-96.
23. Huizinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis. 2008, 32:461-470.
24. Huizinga R., Linington C., Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol. 2008, 29:54-60.
25. Hummelová-Fanfrdlová Z., Rektorová I., Katerřina S., Bartosř A., Vladimír L., Ressner P., Zapletalová J., Vyhnálek M., Hort J. Czech adaptation of Addenbrooke's Cognitive Examination. Cesk. Psychol. 2009, 53:376-388.
26. Jesse S., Brettschneider J., Süssmuth S.D., Landwehrmeyer B.G., von Arnim C.A.F., Ludolph A.C., Tumani H., Otto M. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J. Neurol. 2011, 258:1034-1041.
27. Jianping L., Zhibing Y., Wei Q., Zhikai C., Jie X., Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:127-132.
28. Kolarova M., García-Sierra F., Bartos A., Ricny J., Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis. 2012, 731526. (Epub 2012 May 29).
29. Kumar M., Cohen D., Eisdorfer C. Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome. Alzheimer Dis. Assoc. Disord. 1988, 2:50-55.
30. Levin E.C., Acharya N.K., Han M., Zavareh S.B., Sedeyn J.C., Venkataraman V., Nagele R.G. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 2010, 1345(221-32):221-232.
31. Lewczuk P., Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics 2008, 8:1292-1301.
32. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.-R., Reulbach U., Kornhuber J., Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25:273-281.
33. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
34. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
35. Michaelson D.M., Chapman J., Bachar O., Korczyn A.D., Wertman E. Serum antibodies to cholinergic neurons in Alzheimer's disease. Prog. Clin. Biol. Res. 1989, 317:689-694.
36. Mioshi E., Dawson K., Mitchell J., Arnold R., Hodges J.R. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int. J. Geriatr. Psychiatry 2006, 21:1078-1085.
37. Nagele R.G., Clifford P.M., Siu G., Levin E.C., Acharya N.K., Han M., Kosciuk M.C., Venkataraman V., Zavareh S., Zarrabi S., Kinsler K., Thaker N.G., Nagele E.P., Dash J., Wang H.Y., Levitas A. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition. J. Alzheimers Dis. 2011, 25:605-622.
38. Neff F., Wei X., Nölker C., Bacher M., Du Y., Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun. Rev. 2008, 7:501-507.
39. Oron L., Dubovik V., Novitsky L., Eilam D., Michaelson D.M. Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer's disease. J. Neural Transm. Suppl. 1997, 49:77-84.
40. Perry G., Rizzuto N., Autilio-Gambetti L., Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:3916-3920.
41. Perry G., Friedman R., Kang D.H., Manetto V., utilio-Gambetti L., Gambetti P. Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Res. 1987, 420:233-242.
42. Petzold A., Keir G., Warren J., Fox N., Rossor M.N. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007, 4:185-194.
43. Reddy M.M., Wilson R., Wilson J., Connell S., Gocke A., Hynan L., German D., Kodadek T. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 2011, 144:132-142.
44. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's Disease. J. Mol. Neurosci. 2012, 47:1-14.
45. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 2006, 63:1459-1467.
46. Rosenmann H., Meiner Z., Geylis V., Abramsky O., Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci. Lett. 2006, 410:90-93.
47. Scheltens P., Leys D., Barkhof F., Huglo D., Weinstein H.C., Vermersch P., Kuiper M., Steinling M., Wolters E.C., Valk J. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 1992, 55:967-972.
48. Sigurdsson E.M. Immunotherapy for conformational diseases. Curr. Pharm. Des. 2006, 12:2569-2585.
49. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
50. Soussan L., Tchernakov K., Bachar-Lavi O., Yuvan T., Wertman E., Michaelson D.M. Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease. Mol. Neurobiol. 1994, 9:83-91.
51. Stefansson K., Marton L.S., Dieperink M.E., Molnar G.K., Schlaepfer W.W., Helgason C.M. Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals. Science 1985, 228:1117-1119.
52. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev. 2008, 7:415-420.
53. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 1998, 19:205-216.
54. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
55. Toh B.H., Gibbs C.J., Gajdusek D.C., Goudsmit J., Dahl D. The 200- and 150-kDa neurofilament proteins react with IgG autoantibodies from patients with kuru, Creutzfeldt-Jakob disease, and other neurologic diseases. Proc. Natl. Acad. Sci. 1985, 82:3485-3489.
56. Tumani H., Teunissen C., Süssmuth S., Otto M., Ludolph A.C., Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn. 2008, 8:479-494.
57. van Zwam M., Huizinga R., Melief M.J., Wierenga-Wolf A.F., van M.M., Voerman J.S., Biber K.P., Boddeke H.W., Hopken U.E., Meisel C., Meisel A., Bechmann I., Hintzen R.Q., 't Hart B.A., Amor S., Laman J.D., Boven L.A. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J. Mol. Med. (Berl) 2009, 87:273-286.